our efforts on the children's hospitals and
academic medical centers with large pediatric units which facilitate the
majority of acute and chronic pediatric care. Many of the patients served
in these hospitals undergo peripheral venous access procedures repeatedly,
and are undertreated, indicating a significant unmet medical need," said
Nancy E. Donahue, senior vice president, sales and marketing. Anesiva
estimates that approximately 18 million pediatric peripheral venous access
procedures are performed annually in U.S. hospitals.
Anesiva and its co-promotion partner Sagent Pharmaceuticals, Inc. are
working in tandem to educate caregivers about the importance of addressing
peripheral venous access pain in children, and to ensure Zingo availability
through hospital pharmacies. Anesiva's seasoned team of 15 hospital-based
regional account managers with an average of 14 years' industry experience,
led by two directors who have a combined 30 years' experience, will drive
the launch of this product in the United States. Sagent has assigned 15
field representatives, all of whom have an average of more than 18 years'
hospital selling experience and whose national account representatives have
an average of 25 years of hospital sales experience.
Zingo is currently manufactured with established, approved processes.
Anesiva continues to pursue Zingo manufacturing scale-up in order to reduce
cost of goods and meet anticipated increasing market demand.
Anesiva intends to grow a global brand for Zingo through geographically
based license and distribution agreements with companies that have
expertise in hospital-based markets in their territories, and has already
entered into agreements for several major markets. Sigma Tau SpA will
market Zingo in most major European markets; Medical Futures, Inc. is
responsible for commercializing Zingo in Canada; and Green Vision Company
will commercialize Zingo in several countries in the Middle East. Planning
for local rePage: 1 2 3 4 5 Related biology technology :1
. Anesiva Names Michael L. Kranda as President, Chief Executive Officer and Member of Its Board of Directors2
. Anesiva and Transcription Factor Therapeutics, Inc. Announce Licensing Agreement for Development and Commercialization of NF-kappa B Clinical Program3
. Anesiva Announces First Quarter 2008 Financial Results4
. Anesiva Announces First Quarter 2008 Financial Results Conference Call and Webcast5
. Anesiva Announces Expansion of Zingo Agreement in Europe6
. Anesiva Announces New Zingo Marketing and Distribution Agreement7
. Anesiva Announces Submission of Supplemental New Drug Application for Zingo(TM) to Reduce Pain Associated With Needle Insertion Procedures in Adults8
. Anesiva Announces March 5, 2008 Presentation at Susquehanna Financial Group Healthcare Conference9
. Anesiva Announces Fourth Quarter and Year-End 2007 Financial Results and Provides 2008 Outlook10
. Anesiva Appoints Daniel Janney to Board of Directors11
. Anesiva Announces Fourth Quarter and Year End 2007 Financial Results Conference Call and February 2008 Conference Participation